A digital magazine unpacking the big ideas changing our present and shaping our future.
Olga Aleksandrova for Vox
Hello,
GLP-1 drugs like Ozempic, Wegovy, and Mounjaro have been wildly successful. But as popular as they are, Americans still have very negative feelings about the people using them. In this month’s Highlight cover story, Dylan Scott explains why ‘Ozempic stigma’ hasn’t gone away, how it’s impacting GLP-1 users, and whether it could begin to fade as more and more people take the drugs.
